Shanghai, China, August 3, 2011: Hutchison MediPharma Limited (“HMP”) announced that it has recently been selected by the judging panel as one of the 12 finalists in the highly prestigious Asian Innovation Awards for its novel drug HMPL-004. The Wall Street Journal Asia’s Asian Innovation Awards recognize innovations that break with conventional processes in creative ways. An annual contest, the Asian Innovation Awards seeks to find the next big innovative idea in Asia by selecting from entries regarding breakthroughs in all facets of society. This year, finalists were selected from a pool of nearly 260 entries from 18 countries and territories throughout Asia based on three basic factors: degree of innovation, quality of execution, and potential impact on quality of life or productivity. HMP was selected out of a large pool of applicants for its work in researching and developing HMPL-004, a first in class oral drug product that treats inflammatory Bowel Disease (IBD), including both Ulcerative Colitis and Crohn’s disease. HMPL-004 has shown highly successful results in three Phase II multi center global clinical trials. HMP and the other 11 finalists will attend an award ceremony in November in Hong Kong. More information on the awards and the Wall Street Journal Asia’s article on HMP is available at http://online.wsj.com/article/SB10001424053111904888304576477660151748104.html
About The Wall Street Journal Asia (asia.WSJ.com)
The Wall Street Journal Asia is the leader in global business news for Asia. Since 1976, it has provided indispensable news and analysis of regional and global business developments for an influential pan-Asian audience of corporate and government decision-makers. Edited and published in Hong Kong, The Wall Street Journal Asia is printed in 11 Asian cities and distributed throughout the Asia Pacific region. More than 75% of its subscribers are Asian.
About Hutchison Medi Pharma (HMP)
HMP is a novel pharmaceutical research & development company focused on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of well over 200 scientists, its pipeline includes novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.